Index falls as earnings results weigh; pound above $1.33, Bodycote soars
TORONTO - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI), a company specializing in the development and commercialization of health and wellness products derived from natural sources, announced today the appointment of Anna Biehn as its new Chief Executive Officer, set to take effect on May 5, 2025. The company, currently valued at $9.1 million, has shown promising revenue growth of 34% over the last twelve months, according to InvestingPro data. Biehn, who brings over 25 years of experience in the consumer products and biosciences industries, succeeds Gilles Gagnon, who has been at the helm since 2008.
Biehn’s career includes significant roles such as the Chief Financial Officer of NuTek Natural Ingredients and Vice President of Strategy and Marketing. Her expertise lies in leveraging consumer insights for product development and marketing, particularly in natural-based products. Ronnie Miller, Chair of the Board of COSCIENS, expressed confidence in Biehn’s ability to steer the company into its next growth phase. InvestingPro analysis suggests the company is currently undervalued, with analysts predicting profitability this year despite recent challenges.
Gagnon, who will transition into a strategic advisory role, praised Biehn’s appointment, highlighting her track record in commercializing natural ingredients. He remains confident that her experience will be instrumental in establishing COSCIENS as a leader in the life sciences sector focused on natural products.
Biehn expressed gratitude for the opportunity to join COSCIENS at a critical juncture, emphasizing the potential for innovation and value creation within the natural products market. She aims to harness the company’s existing portfolio and novel technology to position COSCIENS as a global frontrunner in the industry.
Previously, Biehn has held leadership positions at Conagra Brands and served on several boards, demonstrating a broad understanding of strategy and market growth. Her educational background includes a BA in Political Science and an MBA.
COSCIENS Biopharma, born from the merger of Aeterna Zentaris and Ceapro Inc., has a diverse portfolio that includes cosmeceutical, nutraceutical, and pharmaceutical products. The company is known for its proprietary extraction technology applied to plant resources, contributing to well-known skincare brands and potential nutraceutical and pharmaceutical developments. Financial metrics from InvestingPro show the company maintains a strong current ratio of 3.32 and holds more cash than debt, though it faces near-term challenges with cash burn. InvestingPro subscribers have access to over 10 additional key insights about COSCIENS’s financial health and market position.
This leadership transition is based on a press release statement from COSCIENS Biopharma Inc. and reflects the company’s strategic direction and focus on natural-based product innovation within the life sciences domain.
In other recent news, COSCIENS Biopharma Inc. has reported its financial results for the fourth quarter and full year 2024. The company outlined its focus on oat-based nutraceutical products and the commercialization of Macrilen® (macimorelin), while discontinuing certain programs to concentrate resources on high-potential areas. In addition, COSCIENS is progressing with the Phase 2a clinical efficacy study for its avenanthramide-based product, following a successful Phase 1 trial. The study is being conducted at the Montreal Heart Institute and aims to evaluate the product’s potential efficacy in treating mild to moderate inflammation. Meanwhile, COSCIENS has flagged a potential delay in filing its year-end financial documents, citing challenges that might affect the timely submission. The company also shared updates on its Edmonton and Natex Termitz facilities, which are expected to enhance the scale-up of its PGX Technology. Elsewhere, Osisko Gold Royalties Ltd has announced its upcoming Annual and Special Meeting of Shareholders, scheduled for May 8, 2025. The company has filed the necessary documentation with the SEC to ensure transparency and shareholder participation in the meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.